Xenon Pharmaceuticals (XENE) reported a Q3 net loss late Tuesday of $0.81 per diluted share, widening from the loss of $0.73 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.81.
No revenue was recorded in the three months ended Sept. 30, as expected.
The company had $803.3 million in cash and cash equivalents and marketable securities at the end of September and expects to have sufficient cash to fund operations into 2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。